89bio

89bio is a clinical-stage biopharmaceutical company dedicated to rapidly advancing its lead candidate, BIO89-100, through clinical development for the treatment of nonalcoholic steatohepatitis (NASH, a severe form of NAFLD characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, HCC, and death). BIO89-100 is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) specifically designed for this purpose.